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Background:
In the United States, 1.6% of the population is infected with the 
hepatitis C virus (HCV), representing approximately 4-5 million 
people. Since most of these individuals remain unaware of their 
infection, they can serve as an ongoing source of transmission to 
others. HCV-infection places them at risk of developing progressive 
fibrosis leading to cirrhosis and possibly hepatocellular carcinoma. 
Additionally, undiagnosed individuals cannot benefit from potentially 
curative peginterferon/ribavirin therapy. The Lehigh Valley is the third 
most populated metropolitan region in Pennsylvania, consisting 
of Lehigh, Northampton, and Carbon counties in eastern PA. The 
local prevalence has been previously estimated at 0.78%, far less 
than NHANES data would predict. Our objective is to establish a 
prevalence of HCV in the community served by the 986 bed tertiary-
care system of Lehigh Valley Health Network (LVHN), the largest 
health network in Pennsylvania. 
CONCLUSIONS:
HCV seroprevalence in LVHN far exceeds previous local estimates 
and is nearly twice the national prevalence.  Whereas illicit drug 
use is commonly considered to be more prevalent in urban areas, 
HCV-positive subjects in this study were scattered widely among 
the urban, suburban, and rural areas served by LVHN.  Thus, a 
significant number of HCV-positive individuals may be missed if 
local testing efforts targeted urban centers alone.  Broad testing for 
HCV, particularly among individuals born between 1954 and 1973, 
would result in the diagnosis of a significant number of HCV-infected 
individuals and allow referral for potentially curative peginterferon alfa 
and ribavirin combination therapy.
Results:
 •  Twenty-eight samples (2.8%) tested positive for HCV.
 •  The highest HCV prevalence was seen among those aged 45-54 years 
old (8.2%), representing 60.7% of all HCV-positive tests. The next 
highest prevalence was among those aged 35-44 years old: 3.6% [x2 
p<0.001].  
 •  Men were more than twice as likely as women to be HCV-positive (OR 
2.2; CI [1.03,4.81]). 
 •  HCV seroprevalence was evenly distributed among inpatient and 
outpatient settings (x2 p>0.05) and among urban, suburban, and rural 
areas.
 •  Three subjects (10.7% of HCV-positive subjects), all inpatients who 
lived in an urban area, were co-infected with HIV. HIV prevalence 
results have been previously presented elsewhere.
Table 1: Planned Sample Distribution based on LVHN Discharge Data
(Dec. 2005 - Nov. 2006)
Methods:
Figure 1a: Sample Population Distributed by Age
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 •  Based on a 99% confidence interval with a 5% margin for error, an 
adequate sample size was determined to be 1000 subjects.
 •  1000 consecutive leftover blood samples were studied: 399 inpatients 
and 601 outpatients (including Emergency Department). 
 •  Samples were stratified by age and sex based on hospital admission 
statistics. Baseline demographics including age, sex, zip code of 
residence, and site of care (inpatient vs. outpatient) were collected.
 •  De-identified samples were analyzed for HCV via Abbott’s Microparticle 
Enzyme ImmunoAssay (RIBA performed on those not meeting the 
CDC’s recommended signal to cut-off ratio of 9.9 for true antibody 
positivity) and for human immunodeficiency virus (HIV) via ELISA with 
confirmatory Western blot.
 •  Univariate and multivariate analyses were conducted in SPSS 
15.0 statistical software, utilizing T-test, Pearson’s Chi-sqaure and 
correlation analyses, and reporting Poisson’s 95% confidence intervals 
where appropriate.
Figure 1b: HCV-positive Results Distributed by Age
























































Age Group Male Female
Group I       18-24 9 18
Group II      25-34 13 32
Group III     35-44 23 34
Group IV     45-54 37 40
Group V      55-64 39 39
Group VI     65-80 58 57
TOTAL 180 220
Outpatient
Group I       18-24 25 35
Group II      25-34 32 48
Group III     35-44 42 69
Group IV     45-54 48 83
Group V      55-64 40 65
Group VI     65-80 45 68
TOTAL 232 368
